Pharmaxis Ltd
ASX:PXS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Pharmaxis Ltd
ASX:PXS
|
AU |
|
Plains All American Pipeline LP
NASDAQ:PAA
|
US |
|
R
|
Reservoir Link Energy Bhd
KLSE:RL
|
MY |
|
B
|
BNP Paribas SA
XETRA:BNP
|
FR |
|
Eco Depot Inc
OTC:ECDP
|
US |
|
Adya Inc
XTSX:ADYA
|
CA |
|
A
|
AREIT, Inc
XPHS:AREIT
|
PH |
|
Secure Trust Bank PLC
LSE:STB
|
UK |
|
Estia Health Ltd
ASX:EHE
|
AU |
|
Katapult Holdings Inc
NASDAQ:KPLT
|
US |
Pharmaxis Ltd
Pharmaxis Ltd. is a pharmaceutical research company, which engages in the development and commercialization of therapeutic products for chronic respiratory disorders, autoimmune diseases, and improved lung function test. The company is headquartered in Frenchs Forest, New South Wales. The company went IPO on 2003-11-10. The firm has two approved respiratory products, Bronchitol and Aridol. The Bronchitol is used for the treatment of cystic fibrosis to help patient’s clear mucus from their lungs. Aridol is a lung function test designed to help doctors diagnose and manage asthma by detecting active airway inflammation through measuring airway hyper-responsiveness. The firm's development pipeline assets include a topical pan-Lysyl Oxidase (LOX) inhibitor in development for scar revision, keloid scarring and scarring from burn wounds; a series of Lysyl Oxidase Like 2 (LOXL2) inhibitors targeting fibrotic diseases of the kidney, lung, liver, and heart; and an anti-inflammatory dual Semicarbazide-Sensitive Amine Oxidase (SSAO)/ Monoamine oxidase B (MAOB) inhibitor targeting Duchenne Muscular Dystrophy.
Pharmaxis Ltd. is a pharmaceutical research company, which engages in the development and commercialization of therapeutic products for chronic respiratory disorders, autoimmune diseases, and improved lung function test. The company is headquartered in Frenchs Forest, New South Wales. The company went IPO on 2003-11-10. The firm has two approved respiratory products, Bronchitol and Aridol. The Bronchitol is used for the treatment of cystic fibrosis to help patient’s clear mucus from their lungs. Aridol is a lung function test designed to help doctors diagnose and manage asthma by detecting active airway inflammation through measuring airway hyper-responsiveness. The firm's development pipeline assets include a topical pan-Lysyl Oxidase (LOX) inhibitor in development for scar revision, keloid scarring and scarring from burn wounds; a series of Lysyl Oxidase Like 2 (LOXL2) inhibitors targeting fibrotic diseases of the kidney, lung, liver, and heart; and an anti-inflammatory dual Semicarbazide-Sensitive Amine Oxidase (SSAO)/ Monoamine oxidase B (MAOB) inhibitor targeting Duchenne Muscular Dystrophy.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
